The inflammatory marker SIRI acts as a statistical mediator between ApoB/ApoA1 ratio and atrial fibrillation, and combined biomarkers show higher discriminative ability for the presence of atrial fibrillation than single indicators - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

The role of the systemic inflammation response index (SIRI) as a mediator between the ApoB/ApoA1 ratio and atrial fibrillation, with combined biomarkers demonstrating superior discriminative power compared to individual markers

  • By

  • Chenyang Zheng

  • Meixue Jia

  • Bin Ning

  • August 13, 2026

Share

  • 1

    The study examined the systemic inflammation response index (SIRI) as a mediator between the ApoB/ApoA1 ratio and atrial fibrillation (AF).

  • 2

    A total of 638 individuals were analyzed, including 212 with persistent AF, 212 with paroxysmal AF, and 214 controls without AF.

  • 3

    SIRI was found to be a partial mediator in the inverse relationship between the ApoB/ApoA1 ratio and AF.

  • 4

    The combined model of ApoB/ApoA1 and SIRI demonstrated superior discriminative power for detecting AF compared to individual markers.

  • 5

    The findings indicate a significant link between elevated SIRI, decreased ApoB/ApoA1 levels, and higher odds of AF.

Original Source(s)

The inflammatory marker SIRI acts as a statistical mediator between ApoB/ApoA1 ratio and atrial fibrillation, and combined biomarkers show higher discriminative ability for the presence of atrial fibrillation than single indicators

  • by Chenyang Zheng, Meixue Jia, Bin Ning

  • August 13, 2026

Related Content

Tree Canopy Gains Linked to Lower Mortality

The association was most pronounced in Chicago’s hottest neighborhoods, where canopy losses were linked to higher predicted mortality.

Redefining Fontan Care: The Socio-Economic Impact of SVHD on Families

Survey results reveal the long-term socio-economic and psychological impacts of single ventricle congenital heart disease (SVHD) on families. See how cardiologists Deepti Bhat, MD, and Naim Duran, MD, contributors to this research, are using findings to transform Fontan Clinic care at Phoenix Children’s.

  • by

  • August 12, 2026

  • 6 min
Can SGLT2 Inhibitors Affect Dementia?

A target trial emulation using Veterans Affairs electronic health records examined neuropsychiatric outcomes associated with SGLT2 inhibitor use.